effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy苯磷硫胺在高级糖基化终末产物效应和内皮功能障碍和炎症在糖尿病肾病的标志.pdfVIP

Effect of Benfotiamine on Advanced Glycation Endproducts and Markers of Endothelial Dysfunction and Inflammation in Diabetic Nephropathy 1,2,3 1,2,4 2,5 1,2,3 1 Alaa Alkhalaf *, Nanne Kleefstra , Klaas H. Groenier , Henk J. G. Bilo , Reinold O. B. Gans , 6 7 7 1 1 Peter Heeringa , Jean L. Scheijen , Casper G. Schalkwijk , Gerjan J. Navis , Stephan J. L. Bakker 1 Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, 2 Diabetes Centre, Isala Clinics, Zwolle, The Netherlands, 3 Department of Internal Medicine, Isala Clinics, Zwolle, The Netherlands, 4 Langerhans Medical Research Group, Zwolle, The Netherlands, 5 Department of General Practice, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, 6 Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, 7 Department of Internal Medicine, University Hospital Maastricht, Maastricht, The Netherlands Abstract Background: Formation of advanced glycation endproducts (AGEs), endothelial dysfunction, and low-grade inflammation are intermediate pathways of hyperglycemia-induced vascular complications. We investigated the effect of benfotiamine on markers of these pathways in patients with type 2 diabetes and nephropathy. Methods: Patients with type 2 diabetes and urinary albumin excretion in the high-normal and microalbuminuric range (15– 300 mg/24h) were randomized to receive benfotiamine (n = 39) or placebo (n = 43). Pla